Cargando…

β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms

Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear whether β-caryophyllene (BCP), a natural product with a CB2 receptor agonist profile, has therapeutic effects on methamphetamine (METH) abuse and dependence. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiang-Hu, Galaj, Ewa, Bi, Guo-Hua, He, Yi, Hempel, Briana, Wang, Yan-Lin, Gardner, Eliot L., Xi, Zheng-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458938/
https://www.ncbi.nlm.nih.gov/pubmed/34566647
http://dx.doi.org/10.3389/fphar.2021.722476
_version_ 1784571411475464192
author He, Xiang-Hu
Galaj, Ewa
Bi, Guo-Hua
He, Yi
Hempel, Briana
Wang, Yan-Lin
Gardner, Eliot L.
Xi, Zheng-Xiong
author_facet He, Xiang-Hu
Galaj, Ewa
Bi, Guo-Hua
He, Yi
Hempel, Briana
Wang, Yan-Lin
Gardner, Eliot L.
Xi, Zheng-Xiong
author_sort He, Xiang-Hu
collection PubMed
description Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear whether β-caryophyllene (BCP), a natural product with a CB2 receptor agonist profile, has therapeutic effects on methamphetamine (METH) abuse and dependence. In this study, we used animal models of self-administration, electrical brain-stimulation reward (BSR) and in vivo microdialysis to explore the effects of BCP on METH-taking and METH-seeking behavior. We found that systemic administration of BCP dose-dependently inhibited METH self-administration under both fixed-ratio and progressive-ratio reinforcement schedules in rats, indicating that BCP reduces METH reward, METH intake, and incentive motivation to seek and take METH. The attenuating effects of BCP were partially blocked by AM 630, a selective CB2 receptor antagonist. Genetic deletion of CB2 receptors in CB2-knockout (CB2-KO) mice also blocked low dose BCP-induced reduction in METH self-administration, suggesting possible involvement of a CB2 receptor mechanism. However, at high doses, BCP produced a reduction in METH self-administration in CB2-KO mice in a manner similar as in WT mice, suggesting that non-CB2 receptor mechanisms underlie high dose BCP-produced effects. In addition, BCP dose-dependently attenuated METH-enhanced electrical BSR and inhibited METH-primed and cue-induced reinstatement of drug-seeking in rats. In vivo microdialysis assays indicated that BCP alone did not produce a significant reduction in extracellular dopamine (DA) in the nucleus accumbens (NAc), while BCP pretreatment significantly reduced METH-induced increases in extracellular NAc DA in a dose-dependent manner, suggesting a DA-dependent mechanism involved in BCP action. Together, the present findings suggest that BCP might be a promising therapeutic candidate for the treatment of METH use disorder.
format Online
Article
Text
id pubmed-8458938
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84589382021-09-24 β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms He, Xiang-Hu Galaj, Ewa Bi, Guo-Hua He, Yi Hempel, Briana Wang, Yan-Lin Gardner, Eliot L. Xi, Zheng-Xiong Front Pharmacol Pharmacology Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear whether β-caryophyllene (BCP), a natural product with a CB2 receptor agonist profile, has therapeutic effects on methamphetamine (METH) abuse and dependence. In this study, we used animal models of self-administration, electrical brain-stimulation reward (BSR) and in vivo microdialysis to explore the effects of BCP on METH-taking and METH-seeking behavior. We found that systemic administration of BCP dose-dependently inhibited METH self-administration under both fixed-ratio and progressive-ratio reinforcement schedules in rats, indicating that BCP reduces METH reward, METH intake, and incentive motivation to seek and take METH. The attenuating effects of BCP were partially blocked by AM 630, a selective CB2 receptor antagonist. Genetic deletion of CB2 receptors in CB2-knockout (CB2-KO) mice also blocked low dose BCP-induced reduction in METH self-administration, suggesting possible involvement of a CB2 receptor mechanism. However, at high doses, BCP produced a reduction in METH self-administration in CB2-KO mice in a manner similar as in WT mice, suggesting that non-CB2 receptor mechanisms underlie high dose BCP-produced effects. In addition, BCP dose-dependently attenuated METH-enhanced electrical BSR and inhibited METH-primed and cue-induced reinstatement of drug-seeking in rats. In vivo microdialysis assays indicated that BCP alone did not produce a significant reduction in extracellular dopamine (DA) in the nucleus accumbens (NAc), while BCP pretreatment significantly reduced METH-induced increases in extracellular NAc DA in a dose-dependent manner, suggesting a DA-dependent mechanism involved in BCP action. Together, the present findings suggest that BCP might be a promising therapeutic candidate for the treatment of METH use disorder. Frontiers Media S.A. 2021-09-09 /pmc/articles/PMC8458938/ /pubmed/34566647 http://dx.doi.org/10.3389/fphar.2021.722476 Text en Copyright © 2021 He, Galaj, Bi, He, Hempel, Wang, Gardner and Xi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
He, Xiang-Hu
Galaj, Ewa
Bi, Guo-Hua
He, Yi
Hempel, Briana
Wang, Yan-Lin
Gardner, Eliot L.
Xi, Zheng-Xiong
β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
title β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
title_full β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
title_fullStr β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
title_full_unstemmed β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
title_short β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
title_sort β-caryophyllene, an fda-approved food additive, inhibits methamphetamine-taking and methamphetamine-seeking behaviors possibly via cb2 and non-cb2 receptor mechanisms
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458938/
https://www.ncbi.nlm.nih.gov/pubmed/34566647
http://dx.doi.org/10.3389/fphar.2021.722476
work_keys_str_mv AT hexianghu bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT galajewa bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT biguohua bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT heyi bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT hempelbriana bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT wangyanlin bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT gardnereliotl bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms
AT xizhengxiong bcaryophylleneanfdaapprovedfoodadditiveinhibitsmethamphetaminetakingandmethamphetamineseekingbehaviorspossiblyviacb2andnoncb2receptormechanisms